Buy Stocks Easy | About Us
August 17, 2022
Buy Stocks Easy | Online Stocks

ZLAB


Buy Zai Lab Limited Stock (symbol: ZLAB) Easy Online

Company Name: Zai Lab Limited

Symbol: ZLAB

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2017

ZLAB Current Share Price

Today's ZLAB ( Zai Lab Limited ) opening price: $39.6900

Yesterday's ZLAB ( Zai Lab Limited ) closing price: $39.5600

Zai Lab Limited Stock ( symbol: ZLAB ) Price Chart since IPO (2017):

12 Months Zai Lab Limited Stock ( symbol: ZLAB ) Price Chart

Popular Questions about Zai Lab Limited Public Stock ( ZLAB )

A: Zai Lab Limited stock symbol (also called stock or share ticker) is ZLAB

A: Zai Lab Limited IPO (Initial Public Offering) took place on 2017

A: Zai Lab Limited's stock (ZLAB symbol) price at ther IPO (initial Public Offering) was $39.6900

Q: Is ZLAB stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Zai Lab Limited stock (symbol: ZLAB) at the beginning of 2019, at the opening share price of $26.9900, with a minimum of $200, by now your shares would be worth $1682 and your profit would be $1482 - SHOW ONLY IF PROFIT.

Buy Zai Lab Limited Stock Easy Online

Zai Lab Limited Stock Ticker Price Chart since IPO:





Zai Lab Limited Stock Price Yesterday



 


Zai Lab Limited Stock Price – Last Week




 


Zai Lab Limited Stock Price – Last Month




 


Zai Lab Limited Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2020/01/14/1970179/0/en/Zai-Lab-Appoints-Lonnie-Moulder-to-Board-of-Directors.html
                            

                                
Zai Lab Appoints Lonnie Moulder to Board of Directors

                                
                                
SHANGHAI, China and SAN FRANCISCO, Jan.  14, 2020  (GLOBE NEWSWIRE)...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2020/01/09/1968366/0/en/Zai-Lab-and-Novocure-Announce-First-Patient-Enrolled-in-a-Phase-2-Pilot-Trial-of-Tumor-Treating-Fields-Together-with-Chemotherapy-as-First-Line-Treatment-of-Gastric-Cancer.html
                            

                                
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

                                
                                
SHANGHAI, China and ST. HELIER, Jersey, Jan.  09, 2020  (GLOBE NEWS...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/27/1964630/0/en/Zai-Lab-Announces-NMPA-Approval-of-ZEJULA-Niraparib-in-China-as-Maintenance-Therapy-for-Patients-with-Recurrent-Ovarian-Cancer.html
                            

                                
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer

                                
                                
ZEJULA is a potential best-in-class PARP inhibitor for ovarian canc...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/16/1960865/0/en/Zai-Lab-Announces-the-Appointment-of-Timothy-Yap-M-D-Ph-D-to-its-Scientific-Advisory-Board.html
                            

                                
Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board

                                
                                
Dr. Yap will help advance Zai Lab’s preclinical and clinical pipeli...


                            

                        
                    

                


                            

                    


                        
                            https://investorplace.com/2019/12/7-exciting-biotech-companies-to-buy/
                            

                                
7 Exciting Biotech Stocks to Buy Now

                                
                                
Many of these biotech companies are beating the Nasdaq Biotech Inde...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/25/1935677/0/en/Zai-Lab-Partner-MacroGenics-Announces-Initiation-of-Phase-2-3-MAHOGANY-Study-of-Margetuximab-in-Gastric-or-Gastroesophageal-Junction-Cancer.html
                            

                                
Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

                                
                                
SHANGHAI, China and SAN FRANCISCO, Oct.  25, 2019  (GLOBE NEWSWIRE)...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/24/1934978/0/en/Zai-Lab-Partner-GSK-Announces-U-S-Food-and-Drug-Administration-Approval-of-Additional-Indication-for-Zejula-niraparib-for-Late-line-Treatment-for-Women-with-Recurrent-Ovarian-Cance.html
                            

                                
Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer

                                
                                
SHANGHAI, China, and SAN FRANCISCO, Oct.  24, 2019  (GLOBE NEWSWIRE...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/04/1925251/0/en/Dr-Samantha-Du-Zai-Lab-Founder-and-CEO-to-Participate-in-Forbes-Global-CEO-Conference.html
                            

                                
Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

                                
                                
SHANGHAI, China and SAN FRANCISCO, Oct.  04, 2019  (GLOBE NEWSWIRE)...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/29/1922165/0/en/Phase-3-PRIMA-trial-of-Zejula-niraparib-is-the-first-study-to-show-a-PARP-inhibitor-significantly-improves-PFS-regardless-of-biomarker-status-when-given-as-monotherapy-in-women-wit.html
                            

                                
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer

                                
                                
SHANGHAI, China, and SAN FRANCISCO, Sept.  29, 2019  (GLOBE NEWSWIR...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.